StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)

Close on Nov 18, 2026Market cap $145.50KP/E –Yield –

AgomAb Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -€59.28M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€59.28M–
FY2024Dec 31, 2024-€48.02M–
FY2023Dec 31, 2023-€31.19M–

More AgomAb Therapeutics figures

See a number that looks wrong?